{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:04:08Z","timestamp":1786993448162,"version":"build-2736575974"},"reference-count":18,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jtha.2023.06.036","type":"journal-article","created":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T19:25:09Z","timestamp":1688844309000},"page":"3067-3071","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Warfarin faring better: vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4126-1285","authenticated-orcid":false,"given":"John W.","family":"Eikelboom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-7550","authenticated-orcid":false,"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.06.036_bib1","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.7326\/M20-7141","article-title":"Frailty and clinical outcomes of direct oral anticoagulants versus warfarin in older adults with atrial fibrillation: a cohort study","volume":"174","author":"Kim","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2023.06.036_bib2","article-title":"Use of direct oral anticoagulants in patients with atrial fibrillation and valvular heart lesions","volume":"5","author":"Di Biase","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jtha.2023.06.036_bib3","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"External reviewers. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.jtha.2023.06.036_bib4","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2023.06.036_bib5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.5334\/gh.807","article-title":"Meta-analysis of the incidence, prevalence, and correlates of atrial fibrillation in rheumatic heart disease","volume":"15","author":"Noubiap","year":"2020","journal-title":"Glob Heart"},{"key":"10.1016\/j.jtha.2023.06.036_bib6","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in rheumatic heart disease-associated atrial fibrillation","volume":"387","author":"Connolly","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.06.036_bib7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ahj.2020.03.018","article-title":"The INVICTUS rheumatic heart disease research program: rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation","volume":"225","author":"Karthikeyan","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.jtha.2023.06.036_bib8","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1093\/cvr\/cvz100","article-title":"TAM receptors in cardiovascular disease","volume":"115","author":"McShane","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jtha.2023.06.036_bib9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1161\/HYPERTENSIONAHA.115.06254","article-title":"Growth arrest-specific 6 exacerbates pressure overload-induced cardiac hypertrophy","volume":"67","author":"Zhao","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.jtha.2023.06.036_bib10","first-page":"e72","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2023.06.036_bib11","first-page":"383","article-title":"Dabigatran in patients with mechanical heart valves","volume":"370","author":"Eikelboom","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.06.036_bib12","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1111\/jth.12961","article-title":"Medical device-induced thrombosis: what causes it and how can we prevent it?","volume":"13","author":"Jaffer","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.06.036_bib13","article-title":"Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation","volume":"4","author":"Jaffer","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jtha.2023.06.036_bib14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ahj.2020.06.014","article-title":"Rationale and design of PROACT Xa: a randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X aortic heart valve","volume":"227","author":"Jawitz","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.jtha.2023.06.036_bib15","first-page":"2","article-title":"Apixaban or warfarin in patients with an On-X mechanical aortic valve","author":"Wang","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jtha.2023.06.036_bib16","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.athoracsur.2019.10.091","article-title":"Rivaroxaban and dabigatran for suppression of mechanical heart valve-induced thrombin generation","volume":"110","author":"Jaffer","year":"2020","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtha.2023.06.036_bib17","doi-asserted-by":"crossref","first-page":"E267","DOI":"10.1210\/jc.2012-3179","article-title":"Circulating growth arrest-specific 6 protein is associated with adiposity, systemic inflammation, and insulin resistance among overweight and obese adolescents","volume":"98","author":"Hsiao","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jtha.2023.06.036_bib18","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.jtha.2023.04.021","article-title":"News at XI: moving beyond factor Xa inhibitors","volume":"21","author":"Fredenburgh","year":"2023","journal-title":"J\u00a0Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623005238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623005238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:40:09Z","timestamp":1761536409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623005238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1538783623005238"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.06.036","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Warfarin faring better: vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.06.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}